they debate me not science. The science tells you that Primary and secondary brain injury is important and the heart protection in stroke is a 4 billion dollar market in stroke which NYR are now more superior than Aptoll the only other drug that has provided 40 percent protection pre-clinically compared to 86 percent in NYR.
Company just did a very strong raise and has 7.4 million in cash for a clear runway through to phase 2. Strong news flow ahead and that’s what’s important with management showing their confidence in this very strong raise at price at minimal dilution. Management on the ball very happy with the progress
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)